TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients

Resistance is a major challenge in the management of mitogen-activated protein kinase inhibitor (MAPKi)-treated metastatic melanoma. Tumor genetic alterations can cause MAPK pathway reactivation, leading to lack of response and poor outcome. Characterization of the mutational profile in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Bianco, Paola, Stagni, Camilla, Giunco, Silvia, Fabozzi, Alessio, Elefanti, Lisa, Pellegrini, Stefania, Vecchiato, Antonella, Pigozzo, Jacopo, Zamuner, Carolina, De Rossi, Anita, De Nicolo, Arcangela, Menin, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226422/
https://www.ncbi.nlm.nih.gov/pubmed/32290374
http://dx.doi.org/10.3390/cancers12040946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226422/
https://www.ncbi.nlm.nih.gov/pubmed/32290374
http://dx.doi.org/10.3390/cancers12040946

Ejemplares similares